Lymphocyte Subset Panel 6 - Total Lymphocyte Enumeration with CD45RA and CD45RO
Also known as: TEXTENDED
Use
Useful for assessing primary T-cell immunodeficiency disorders. CD4 and CD8 T-cell levels are critical for categorizing HIV-related clinical conditions. Monitoring these levels assists in initiating prophylaxis and antiviral therapy, and evaluating treatment efficacy as per CDC guidelines. Regular monitoring is essential in HIV-infected individuals and is recommended every 3 to 6 months.
Special Instructions
Whole blood is added to fluorochrome-labeled antibodies specific to lymphocyte surface antigens. Incubation, lysing, and fixation follow, with enumeration using an internal quantitation standard. Ensure stability as per given timelines for accurate results.
Limitations
This test is not cleared or approved by the FDA but is developed and performed in a CLIA certified lab for clinical purposes. Medications and delayed analysis beyond stability can affect results. Interpretations should be made in the context of clinical findings and other lab data.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 48767-8
- 15195-1
- 32519-1
- 20604-5
- 34475-4
- 41994-5
- 26759-1
- 17157-9
- 8122-4
- 20599-7
- 24467-3
- 14135-8
- 8123-2
- 32518-3
- 20593-0
- 54218-3
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
0.5 mL
Container
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin). Hemogard tubes preferred.
Storage Instructions
Transport at room temperature. Critical to maintain ambient temperature for 72 hours for EDTA; 48 hours for heparin.
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | EDTA: 72 hours; Heparin: 48 hours |
| Refrigerated | Unacceptable |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant